University Cancer & Blood Center, LLC, Athens
Local Institution - 0412, Augusta
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Marietta

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07361510

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

Emory Winship Cancer Institute, Atlanta

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07659782

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Winship Cancer Institute of Emory University, Atlanta

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06765109

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

University Cancer and Blood Center, Athens
Piedmont Healthcare, Inc, Atlanta
Winship Cancer Institute, Atlanta

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06881784

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Tennessee Oncology, PLLC - Dalton, Dalton
Tennessee Oncology, PLLC - Ringgold, Ringgold

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07144280

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Piedmont Atlanta Hospital ( Site 4000), Atlanta
Emory University School of Medicine-Phase I ( Site 0056), Atlanta
Northside Hospital ( Site 0055), Atlanta
ak 3 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06312137

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

University Cancer & Blood Center, LLC, Athens

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07489066

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Grady Health System Correll Pavilion, Atlanta
Piedmont Healthcare, Atlanta
Piedmont Cancer Institute, Atlanta
ak 2 plis

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06667076

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

Emory University Winship Cancer Institute, Atlanta

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06667908

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Research Site, Marietta

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06868277

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

University Cancer & Blood Center, LLC, Athens
Winship Cancer Institute, Atlanta
City of Hope National Medical Center, Atlanta Cancer Center, Newnan

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06890598

Pan-tumor MRD Study

Piedmont Cancer Institute, Atlanta

Ap rekriteEtid obsèvasyon

Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06605404

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Emory University Hospital Midtown, Atlanta
Emory University Hospital/Winship Cancer Institute, Atlanta
Emory Saint Joseph's Hospital, Atlanta

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT03191149

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Atlanta
Research Site, Atlanta

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06357533

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Emory Winship Cancer Institute, Atlanta

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07140016

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Northwest Georgia Oncology Centers, P.C., Marietta

Ap rekriteFaz 2/3

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06712316

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

University Cancer & Blood Center /ID# 270969, Athens
Northwest Georgia Oncology Centers /ID# 275374, Marietta

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06568939

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Winship Cancer Institute at Emory University, Atlanta

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07488676

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Piedmont Healthcare, Atlanta
John B Amos Cancer Center, Columbus

Ap rekriteFaz 2/3

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07100080

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Marietta

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06875310

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Athens
Research Site, Savannah

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06692738

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site, Atlanta
Clinical Study Site, Warner Robins

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06767514

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Piedmont Cancer Institute, Atlanta
Northwest Georgia Oncology Centers, Marietta

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07195695

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

University Cancer & Blood Center (UCBC) - Athens, Athens
Local Institution - 007-786-C, Carrollton
Local Institution - 007-786-A, Cartersville
ak 4 plis

Ap rekriteFaz 2/3

Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT04613596

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Piedmont Cancer Institute OneOncology, Atlanta

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06899126

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

University Cancer and Blood Cent /ID# 261824, Athens

Ap rekriteFaz 2/3

Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06236438

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Emory University, Atlanta

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06303505

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

Piedmont Cancer Institute, PC, Atlanta

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07541170

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Piedmont Cancer Institute, PC, Atlanta
City of Hope® Atlanta, Newnan
Summit Cancer Care PC, Savannah

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06793215

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

University Cancer & Blood Center, LLC, Athens
Emory University School of Medicine- Grady Campus, Atlanta
Winship Cancer Institute, Emory University, Atlanta

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06119581

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

Emory University, Atlanta

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06400472

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site, Marietta
Research Site, Newnan

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07291037

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Emory University, Atlanta

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07070232

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.